Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Dec 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Aluminium phosphate (Primary) ; RSV F protein vaccine-Novavax (Primary) ; Adjuvants
Indications Respiratory syncytial virus infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Novavax

30 Aug 2018 Status changed from active, no longer recruiting to completed.
24 Jul 2017 Topline data published in a Novavax Media Release.
21 Jul 2017 According to a Novavax media release, the company plans to announce topline data from this trial on 24 July 2017 during a conference call and webcast.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com